haloperidol has been researched along with Tachycardia, Ventricular in 4 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Tachycardia, Ventricular: An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation).
| Excerpt | Relevance | Reference |
|---|---|---|
| "A 42-year-old woman who underwent single lung transplantation who received tacrolimus and a 58-year-old woman with pneumonia and multiple comorbidities who received haloperidol both experienced drug-induced prolongation of cardiac repolarization." | 3.72 | Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient. ( Akers, WS; Davis, GA; Flynn, JD; Green, AE; Strobel, G; Winstead, PS, 2004) |
| "Haloperidol has been reported to induce polymorphic ventricular arrhythmias associated with QT prolongation." | 1.31 | Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential. ( Hashimoto, K; Satoh, Y; Sugiyama, A; Tamura, K, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Frommeyer, G | 1 |
| Brücher, B | 1 |
| von der Ahe, H | 1 |
| Kaese, S | 1 |
| Dechering, DG | 1 |
| Kochhäuser, S | 1 |
| Bogossian, H | 1 |
| Milberg, P | 1 |
| Eckardt, L | 1 |
| Akers, WS | 1 |
| Flynn, JD | 1 |
| Davis, GA | 1 |
| Green, AE | 1 |
| Winstead, PS | 1 |
| Strobel, G | 1 |
| Satoh, Y | 1 |
| Sugiyama, A | 1 |
| Tamura, K | 1 |
| Hashimoto, K | 1 |
| Hatta, K | 1 |
| Takahashi, T | 1 |
| Nakamura, H | 1 |
| Yamashiro, H | 1 |
| Asukai, N | 1 |
| Matsuzaki, I | 1 |
| Yonezawa, Y | 1 |
4 other studies available for haloperidol and Tachycardia, Ventricular
| Article | Year |
|---|---|
Low proarrhythmic potential of citalopram and escitalopram in contrast to haloperidol in an experimental whole-heart model.
Topics: Action Potentials; Animals; Citalopram; Haloperidol; Heart; Rabbits; Tachycardia, Ventricular | 2016 |
Prolonged cardiac repolarization after tacrolimus and haloperidol administration in the critically ill patient.
Topics: Administration, Oral; Adult; Critical Illness; Dose-Response Relationship, Drug; Drug Administration | 2004 |
Effect of magnesium sulfate on the haloperidol-induced QT prolongation assessed in the canine in vivo model under the monitoring of monophasic action potential.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dogs; Dopamine Antagonists; Haloperidol; Long QT | 2000 |
The association between intravenous haloperidol and prolonged QT interval.
Topics: Adult; Anti-Anxiety Agents; Antipsychotic Agents; Cohort Studies; Confidence Intervals; Cross-Sectio | 2001 |